Nivolumab (an anti-PD1 monoclonal antibody) is also indicated in bladder cancer with a PDL1 expression >1% in the post-operative adjuvant setting (Bajorin et al., 2021). The gene discussed is CD274; the disease is urinary bladder cancer.